Article ID Journal Published Year Pages File Type
4006653 Archivos de la Sociedad Española de Oftalmología 2016 8 Pages PDF
Abstract
The cost-effectiveness of ocriplasmin has not been demonstrated in Spain. However, good studies performed in other countries found that ocriplasmin is cost-effective in selected patients. Given the current prices in Spain, ocriplasmin could involve a saving for the Spanish NHS.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Ophthalmology
Preview
Revisión de estudios económicos y análisis de impacto presupuestario de la ocriplasmina como tratamiento de la tracción vitreomacular
Authors
, , , , ,